Cartesian Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Gaithersburg, Maryland and currently employs 38 full-time employees. The company went IPO on 2016-06-22. Cartesian Therapeutics, Inc. is a clinical-stage company. The firm is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. The company is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. The company is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Frequently Asked Questions